ArticlePloS one2026
Interaction between genistein and the endothelial activation and stress index in relation to estimated 10-year atherosclerotic cardiovascular disease risk classification.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Endothelial Activation and Stress Index (EASIX) has been proposed as a marker of endothelial stress and may be associated with atherosclerotic cardiovascular disease (ASCVD) risk. Whether urinary genistein modifies this association remains unclear.
methodsMultivariable logistic regression examined the association between EASIX and estimated 10-year ASCVD risk classification. Effect modification by urinary genistein (<54.105 vs. ≥ 54.105 μg/g) was assessed using interaction terms and stratified analyses. Restricted cubic splines (RCS) evaluated dose-response relationships.
resultsIn the fully adjusted model, higher EASIX was independently associated with increased ASCVD risk (OR per unit increase = 1.407; 95% CI: 1.208-1.640; P < 0.001). A significant multiplicative interaction between EASIX and genistein was observed (OR = 1.66; 95% CI: 1.17-2.35; P = 0.005). Stratified analysis showed that this adverse association was slightly attenuated in the higher genistein group (OR = 1.360; 95% CI: 1.066-1.736; P = 0.015) compared to the lower group (OR = 1.397; 95% CI: 1.202-1.624; P < 0.001). RCS analyses showed a non-linear S-shaped association in the lower-genistein group (P nonlinear = 0.020), whereas a predominantly linear relationship was observed in the higher-genistein group (P nonlinear = 0.108).
conclusionsHigher EASIX was associated with elevated estimated 10-year ASCVD risk classification, and this association differed across urinary genistein strata. These findings should be interpreted as hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.